nuclear receptor subfamily 2 group C member 2Genealiases: TAK1 · TR4
Q-omics provides the consensus-scored NR2C2 profile across patient tissues and cancer cell-line models. NR2C2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NR2C2 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, NR2C2 protein abundance shows 21,958 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, LIHC, and GBM as cancer lineages where NR2C2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR2C2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR2C2 survival associations across molecular data types. NR2C2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR2C2 RNA expression–survival associations across cancer types. High NR2C2 expression shows unfavorable associations in ACC, LUSC and KICH, but favorable associations in HNSC, READ and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NR2C2 RNA expression.
This table summarizes NR2C2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NR2C2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR2C2 shows lower tumor expression in KIRC, BRCA, UCEC and THCA and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher NR2C2 RNA expression in tumor versus normal tissue (log2 FC = +0.804, t-test p < 0.001).
This table shows molecular features associated with NR2C2 in patient tissues and cancer cell lines. In patient samples, NR2C2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NR2C2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
